全文获取类型
收费全文 | 704篇 |
免费 | 67篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 22篇 |
妇产科学 | 15篇 |
基础医学 | 70篇 |
临床医学 | 47篇 |
内科学 | 273篇 |
皮肤病学 | 4篇 |
神经病学 | 74篇 |
特种医学 | 23篇 |
外科学 | 84篇 |
综合类 | 21篇 |
预防医学 | 71篇 |
眼科学 | 4篇 |
药学 | 44篇 |
肿瘤学 | 13篇 |
出版年
2021年 | 7篇 |
2020年 | 13篇 |
2019年 | 11篇 |
2017年 | 6篇 |
2015年 | 8篇 |
2014年 | 10篇 |
2013年 | 15篇 |
2012年 | 14篇 |
2011年 | 17篇 |
2010年 | 8篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 12篇 |
2006年 | 17篇 |
2005年 | 27篇 |
2004年 | 18篇 |
2003年 | 31篇 |
2002年 | 22篇 |
2001年 | 49篇 |
2000年 | 28篇 |
1999年 | 29篇 |
1998年 | 8篇 |
1997年 | 12篇 |
1996年 | 11篇 |
1995年 | 16篇 |
1994年 | 9篇 |
1993年 | 10篇 |
1992年 | 25篇 |
1991年 | 23篇 |
1990年 | 18篇 |
1989年 | 21篇 |
1988年 | 16篇 |
1987年 | 31篇 |
1986年 | 25篇 |
1985年 | 14篇 |
1984年 | 22篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1980年 | 8篇 |
1979年 | 6篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 9篇 |
1974年 | 14篇 |
1973年 | 4篇 |
1972年 | 11篇 |
1971年 | 11篇 |
1970年 | 4篇 |
1969年 | 6篇 |
1967年 | 7篇 |
排序方式: 共有771条查询结果,搜索用时 203 毫秒
1.
Emeka C. Anyanwu Rhys F. M. Chua Stephanie A. Besser Deyu Sun James K. Liao Corey E. Tabit 《Clinical cardiology》2021,44(2):193
BackgroundWhile many interventions to reduce hospital admissions and emergency department (ED) visits for patients with cardiovascular disease have been developed, identifying ambulatory cardiac patients at high risk for admission can be challenging.HypothesisA computational model based on readily accessible clinical data can identify patients at risk for admission.MethodsElectronic health record (EHR) data from a tertiary referral center were used to generate decision tree and logistic regression models. International Classification of Disease (ICD) codes, labs, admissions, medications, vital signs, and socioenvironmental variables were used to model risk for ED presentation or hospital admission within 90 days following a cardiology clinic visit. Model training and testing were performed with a 70:30 data split. The final model was then prospectively validated.ResultsA total of 9326 patients and 46 465 clinic visits were analyzed. A decision tree model using 75 patient characteristics achieved an area under the curve (AUC) of 0.75 and a logistic regression model achieved an AUC of 0.73. A simplified 9‐feature model based on logistic regression odds ratios achieved an AUC of 0.72. A further simplified numerical score assigning 1 or 2 points to each variable achieved an AUC of 0.66, specificity of 0.75, and sensitivity of 0.58. Prospectively, this final model maintained its predictive performance (AUC 0.63–0.60).ConclusionNine patient characteristics from routine EHR data can be used to inform a highly specific model for hospital admission or ED presentation in cardiac patients. This model can be simplified to a risk score that is easily calculated and retains predictive performance. 相似文献
2.
White D. MacDonald S. Bull T. Hayman M. de Monteverde-Robb D. Sapsford D. Lavinio A. Varley J. Johnston A. Besser M. Thomas W. 《Journal of thrombosis and thrombolysis》2020,50(2):478-478
Journal of Thrombosis and Thrombolysis - In the original publication of this article, one of the co-author name "D. de Monteverde-Robb" was inadvertently mentioned as "R. de... 相似文献
3.
4.
Liu David Tianxiang Besser Gerold Parzefall Thomas Riss Dominik Mueller Christian A. 《European archives of oto-rhino-laryngology》2020,277(7):1977-1985
European Archives of Oto-Rhino-Laryngology - Epistaxis represents the most frequent ear, nose, throat-related emergency symptom. Seasonal variation in epistaxis incidence, with peaks during winter... 相似文献
5.
6.
7.
R Besser C J Schuster 《EEG-EMG Zeitschrift für Elektroenzephalographie, Elektromyographie und verwandte Gebiete》1979,10(3):158-160
A patient with severe drug intoxication developed the well known EEG stages, starting with burst suppression activity until the pattern with delta waves and sharp waves was reached. At this stage it was treated with diphenylhydantoine intravenously. During injection the sharp elements disappeared and the pattern of faster waves was established. Thus it may be concluded that the sharp wave delta pattern indicates activity similar to that seen in epilepsy and that such a pattern needs anticonvulsant therapy. 相似文献
8.
Brattleboro rats have deficient adrenocorticotropin responses to activation of central alpha 1-adrenoceptors 总被引:1,自引:0,他引:1
This experiment was designed to test further the hypothesis that vasopressin is the major mediator of the ACTH response to activation of central alpha 1-adrenoceptors in the rat. The alpha 1-adrenergic agonist methoxamine was given intracerebro-ventricularly to conscious vasopressin-deficient (homozygous Brattleboro) and normal rats bearing venous and intracerebro-ventricular cannulae. Methoxamine stimulated the secretion of ACTH in the normal, but not in the vasopressin-deficient, rats. The data confirm that vasopressin, rather than CRH-41 or oxytocin, is the major hypothalamic peptide that mediates the effects of central alpha 1-adrenoceptors on the pituitary corticotrophs. 相似文献
9.
E S Penny A M Sopwith R L Patience J A Wass G M Besser L H Rees 《The Journal of endocrinology》1986,111(3):507-511
Four forms of circulating immunoreactive human GH-releasing factor (ir-hGRF) have been identified in each of four normal subjects, with a mean increase in total ir-hGRF of twofold over basal levels following a mixed meal. Plasma samples (200 ml) from each individual were subjected to large-scale Vycor extraction with initial purification by high-performance liquid chromatography on a reversed-phase C18 column, followed by analytical separation of the ir-hGRF components using a C3 wide-pore reversed-phase column, and subsequent radioimmunoassay of the fractions. The mean recovery of total ir-hGRF from the plasma (fasted and non-fasted) was 76 +/- 16% (2 X S.E.M.). Analytical separation of the ir-hGRF revealed four components which co-eluted with synthetic hGRF-37, hGRF-40 and hGRF-44, and a peak eluting between hGRF-40 and -44 which may represent hGRF-42. The hGRF-40 was shown to be the predominant circulating molecular form in the fasted state in each subject, and in three out of four subjects following a mixed meal. The hGRF-44 showed the greatest percentage increase over basal in all four individuals. 相似文献
10.
Florakis D Hung V Kaltsas G Coyte D Jenkins PJ Chew SL Grossman AB Besser GM Monson JP 《Clinical endocrinology》2000,53(4):453-459
OBJECTIVE: To study the effects of short (6 months) and longer-term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH-deficient, hypopituitary adults. DESIGN: On-going open study of GH treatment up to 24 months. Measurements were performed at baseline and at 6, 12, 18 months and 2 years during therapy (data shown at 6 months and 2 years only). Using a dose titration regimen the median GH dose used to achieve and maintain IGF-I levels above the median, but below the upper limit of the age-related reference range (median IGF-I 202.5 microg/l, range 76-397 microg/l), was 1.2 IU daily (range 0.4-3 IU) [0.8 IU/day, males; 1.6 IU/day, females]. PATIENTS: Ninety GH-deficient hypopituitary adults (54 female, median age 48 years, range 19-79 years) entered the study and 24 (14 female, median age 45 years, range 32-79 years) have concluded the 2 year period of assessment. MEASUREMENTS: Body mass index (BMI), waist and hip circumference ratio (WHR), fasting lipids, glucose and glycated haemoglobin (HbA1c) levels were measured at 6 month intervals during GH therapy. RESULTS: Using the dose titration regimen, compared to pretreatment values, total and low density lipoprotein (LDL)-cholesterol levels were significantly lower at 6 months (mean +/- SEM, 5.61+/-0.1 vs. 5.25+/-0.1, and 3.85+/-0.19 vs. 3.43+/-0.26, respectively, P<0.05), and were maintained throughout the study. Male patients had significantly lower pretreatment total and LDL cholesterol levels than females (mean +/- SEM, 5.33+/-0.16 mmol/l vs. 5.7+/-0.12 mmol/l and 3.8+/-0.23 mmol/l vs. 3.92+/-0.29 mmol/l, respectively, P< 0.05). A decrease in total cholesterol was confined to patients with pretreatment total cholesterol levels above 5.8 mmol/l; patients with the highest pretreatment cholesterol levels (> 6.4 mmol/l) obtained the greatest cholesterol reduction (mean +/- SEM, 7.13 +/- 0.14 mmol/l vs. 5.76+/-0.31 mmol/l, P<0.05). A cholesterol-lowering effect of GH therapy was evident in patients who had elevated pre-GH total cholesterol levels even if they were already receiving and continuing lipid lowering medication (mean +/- SEM, 5.62+/-0.22 vs. 5.03+/-0.285, P<0.05). A modest increment in high density lipoprotein (HDL)-cholesterol was evident at 18 months but there was no significant change in triglycerides at any time point. Fasting plasma glucose increased significantly at 6 months but remained within the reference range. Glycated haemoglobin increased significantly at 6 months and was maintained throughout the study; one patient developed frank diabetes mellitus while receiving treatment. There was a weak but significant correlation between the increment in glycated haemoglobin and pretreatment BMI (r = + 0.215, P<0.05). CONCLUSION: The effect of GH on lowering total and low density lipoprotein-cholesterol is more prominent in patients with higher pretreatment cholesterol levels and is evident even in patients receiving other lipid-lowering medication. A modest increment in mean fasting glucose (within the reference range) and mean glycated haemoglobin persisted throughout the study. One patient developed diabetes mellitus. A GH replacement regimen using low dose and careful titration to avoid elevated IGF-I levels and adverse effects is associated with sustained beneficial effects on circulating lipids. 相似文献